X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16218) 16218
Book Chapter (74) 74
Magazine Article (28) 28
Newsletter (28) 28
Dissertation (19) 19
Book / eBook (14) 14
Publication (9) 9
Conference Proceeding (7) 7
Book Review (5) 5
Web Resource (4) 4
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9895) 9895
animals (7708) 7708
renin-angiotensin system - drug effects (7504) 7504
renin-angiotensin system (7189) 7189
male (7074) 7074
female (4407) 4407
rats (4047) 4047
hypertension (3995) 3995
blood pressure - drug effects (3579) 3579
renin-angiotensin system - physiology (3555) 3555
hypertension - drug therapy (2851) 2851
angiotensin (2660) 2660
peripheral vascular disease (2629) 2629
middle aged (2569) 2569
angiotensin-converting enzyme inhibitors - therapeutic use (2526) 2526
blood-pressure (2399) 2399
adult (2207) 2207
hypertension - physiopathology (2100) 2100
pharmacology & pharmacy (2009) 2009
blood pressure (1902) 1902
cardiac & cardiovascular systems (1901) 1901
angiotensin-converting enzyme inhibitors - pharmacology (1843) 1843
aged (1714) 1714
antihypertensive agents - therapeutic use (1677) 1677
urology & nephrology (1560) 1560
physiology (1494) 1494
renin - blood (1438) 1438
angiotensin ii (1408) 1408
risk factors (1368) 1368
renin (1349) 1349
kidney - drug effects (1205) 1205
mice (1185) 1185
rats, sprague-dawley (1140) 1140
antihypertensive agents - pharmacology (1115) 1115
treatment outcome (1113) 1113
oxidative stress (1108) 1108
expression (1106) 1106
angiotensin ii - pharmacology (1083) 1083
aldosterone (1034) 1034
disease models, animal (1025) 1025
angiotensin ii type 1 receptor blockers - therapeutic use (990) 990
heart failure - drug therapy (962) 962
drug therapy, combination (949) 949
time factors (948) 948
angiotensin receptor antagonists (944) 944
heart failure (925) 925
research (925) 925
physiological aspects (910) 910
dose-response relationship, drug (855) 855
angiotensin ii type 1 receptor blockers - pharmacology (848) 848
losartan (844) 844
rats, wistar (841) 841
system (834) 834
endocrinology & metabolism (832) 832
hemodynamics - drug effects (824) 824
blood pressure - physiology (823) 823
medicine & public health (817) 817
captopril - pharmacology (816) 816
angiotensin ii - metabolism (792) 792
diabetes (786) 786
aldosterone - blood (784) 784
captopril (782) 782
enzymes (770) 770
heart-failure (757) 757
health aspects (756) 756
medicine, general & internal (747) 747
kidney (732) 732
heart rate - drug effects (728) 728
angiotensin-ii (722) 722
mortality (721) 721
kidney - metabolism (705) 705
drug therapy (699) 699
hypertension - metabolism (689) 689
renin-angiotensin-aldosterone system (681) 681
inhibition (680) 680
hypertension - complications (676) 676
tetrazoles - pharmacology (676) 676
heart failure - physiopathology (675) 675
myocardial-infarction (671) 671
angiotensin-converting enzyme inhibitors (670) 670
ace inhibitors (656) 656
analysis (643) 643
inflammation (640) 640
medicine, research & experimental (632) 632
receptor (628) 628
angiotensin ii - blood (600) 600
nephrology (587) 587
fibrosis (583) 583
internal medicine (579) 579
care and treatment (577) 577
renin - antagonists & inhibitors (574) 574
angiotensin ii - physiology (572) 572
kidney - physiopathology (568) 568
peptidyl-dipeptidase a - metabolism (560) 560
losartan - pharmacology (559) 559
rats, inbred shr (559) 559
disease (558) 558
angiotensin-converting enzyme (557) 557
medicine (551) 551
disease progression (550) 550
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15568) 15568
Japanese (288) 288
German (189) 189
French (151) 151
Russian (150) 150
Spanish (99) 99
Italian (68) 68
Chinese (66) 66
Portuguese (54) 54
Polish (45) 45
Danish (22) 22
Hungarian (19) 19
Dutch (16) 16
Ukrainian (11) 11
Czech (10) 10
Romanian (10) 10
Bulgarian (8) 8
Turkish (8) 8
Norwegian (6) 6
Swedish (5) 5
Finnish (4) 4
Hebrew (4) 4
Slovak (3) 3
Serbian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American journal of physiology. Heart and circulatory physiology, ISSN 0363-6135, 2016, Volume 311, Issue 4, pp. H871 - H880
We previously reported that endoplasmic reticulum (ER) stress is induced in the subfornical organ (SFO) and the hypothalamic paraventricular nucleus (PVN) of... 
Heart failure | Brain | Sympathetic activity | Hypothalamic paraventricular nucleus | Mitogen-activated protein kinase | Subfornical organ | Endoplasmic reticulum stress | heart failure | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | INDUCED PHOSPHORYLATION | MYOCARDIAL-INFARCTION | ER STRESS | subfornical organ | KINASE | RATS | sympathetic activity | KAPPA-B | brain | endoplasmic reticulum stress | hypothalamic paraventricular nucleus | mitogen-activated protein kinase | UNFOLDED PROTEIN RESPONSE | PERIPHERAL VASCULAR DISEASE | UP-REGULATION | Cholagogues and Choleretics - pharmacology | Tumor Necrosis Factor-alpha - genetics | Heart Failure - physiopathology | Male | NF-KappaB Inhibitor alpha - genetics | Peptidyl-Dipeptidase A - drug effects | Interleukin-1beta - genetics | Sympathetic Nervous System - physiopathology | RNA, Messenger - metabolism | Activating Transcription Factor 6 - genetics | Subfornical Organ - drug effects | Brain - metabolism | Heat-Shock Proteins - genetics | Inflammation - metabolism | Receptor, Angiotensin, Type 1 - genetics | Cyclooxygenase 2 - genetics | p38 Mitogen-Activated Protein Kinases - metabolism | Real-Time Polymerase Chain Reaction | Echocardiography | Signal Transduction | Rats | Cyclooxygenase 2 - drug effects | Heart Failure - metabolism | Rats, Sprague-Dawley | Blotting, Western | Brain - drug effects | Tumor Necrosis Factor-alpha - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Endoplasmic Reticulum Stress | Paraventricular Hypothalamic Nucleus - metabolism | Infusions, Intraventricular | Mitogen-Activated Protein Kinases - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Interleukin-1beta - drug effects | Sympathetic Nervous System - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | X-Box Binding Protein 1 - drug effects | Sympathetic Nervous System - metabolism | Transcription Factor RelA - genetics | Activating Transcription Factor 6 - drug effects | Mitogen-Activated Protein Kinase 3 - drug effects | Taurochenodeoxycholic Acid - pharmacology | Peptidyl-Dipeptidase A - genetics | Renin-Angiotensin System | Receptor, Angiotensin, Type 1 - drug effects | RNA, Messenger - drug effects | Subfornical Organ - metabolism | Heat-Shock Proteins - drug effects | Activating Transcription Factor 4 - genetics | Activating Transcription Factor 4 - drug effects | NF-KappaB Inhibitor alpha - drug effects | Paraventricular Hypothalamic Nucleus - drug effects | p38 Mitogen-Activated Protein Kinases - drug effects | Animals | Transcription Factor RelA - drug effects | X-Box Binding Protein 1 - genetics | Mitogen-Activated Protein Kinases - metabolism | Physiological aspects | Cellular signal transduction | Endoplasmic reticulum | Health aspects | Mitogen-activated protein kinases | Cardiovascular Neurohormonal Regulation
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2018, Volume 2018, Issue 11, p. CD008170
.... Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs... 
Hypertension | Kidney disease | Stroke | Renin‐Angiotensin System | Sodium Chloride Symporter Inhibitors | Cause of Death | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | Calcium Channel Blockers | Myocardial Infarction | Management/treatment of Specific sub‐types of Hypertensive Patients | Management of specific sub‐types of hypertensive patients | Heart Failure | Kidney Failure, Chronic | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Patients with other cardiovascular risk factors (smoking; diabetes; high serum cholesterol levels; arterial fibrillation) | CALCIUM-CHANNEL BLOCKER | INTIMA-MEDIA THICKNESS | LIPID-LOWERING TREATMENT | DEPENDENT DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | END-POINT REDUCTION | CONVERTING ENZYME-INHIBITION | DOUBLE-BLIND | BLOOD-PRESSURE CONTROL | QUALITY-OF-LIFE | LEFT-VENTRICULAR HYPERTROPHY | Myocardial Infarction - epidemiology | Stroke - prevention & control | Calcium Channel Blockers - adverse effects | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Sodium Chloride Symporter Inhibitors - adverse effects | Sodium Chloride Symporter Inhibitors - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Heart Failure - prevention & control | Stroke - chemically induced | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Kidney Failure, Chronic - epidemiology | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Renin-Angiotensin System - drug effects | Aged | Hypertension - mortality | Heart Failure - chemically induced | Heart Failure - mortality
Journal Article
Osteoporosis international, ISSN 1433-2965, 2015, Volume 27, Issue 3, pp. 1083 - 1092
The skeletal renin-angiotensin system contributes to the development of osteoporosis... 
Kallikrein-kinin system | Medicine & Public Health | Orthopedics | Rheumatology | Aliskiren | Trabecular bone | Ovariectomized | Renin-angiotensin system | Endocrinology | CONVERTING ENZYME-INHIBITOR | AT RECEPTOR | INJURY | TYPE-1 RECEPTOR BLOCKER | COMBINATION | OSTEOPOROSIS | MINERAL DENSITY | THERAPY | DRUGS | ENDOCRINOLOGY & METABOLISM | BRADYKININ | Kallikrein-Kinin System - physiology | Bone Density - physiology | Cancellous Bone - metabolism | Humans | Osteoporosis - drug therapy | Cancellous Bone - drug effects | Femur - diagnostic imaging | Cancellous Bone - diagnostic imaging | Osteoporosis - diagnostic imaging | Female | Blood Pressure - drug effects | Osteoporosis - physiopathology | Amides - pharmacology | Biomarkers - metabolism | Drug Evaluation, Preclinical - methods | Lumbar Vertebrae - diagnostic imaging | Ovariectomy | Fumarates - therapeutic use | Mice, Inbred C57BL | RNA, Messenger - genetics | Bone Density Conservation Agents - therapeutic use | Femur - drug effects | Renin-Angiotensin System - genetics | Renin-Angiotensin System - physiology | Amides - therapeutic use | Lumbar Vertebrae - drug effects | Kallikrein-Kinin System - drug effects | Renin - blood | X-Ray Microtomography - methods | Bone Density Conservation Agents - pharmacology | Gene Expression Regulation - drug effects | Bone Density - drug effects | Animals | Proteins - metabolism | Renin - antagonists & inhibitors | Fumarates - pharmacology | Renin-Angiotensin System - drug effects | Osteoclasts - drug effects | Osteoporosis | Analysis | Kallikrein | Postmenopausal women | Drug therapy | Health aspects | Skeletal system | Hormones
Journal Article
Circulation research, ISSN 1524-4571, 2015, Volume 116, Issue 6, pp. 1074 - 1095
Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardio... 
blood pressure | treatment | hypertension | interventional | drug | CARDIAC & CARDIOVASCULAR SYSTEMS | CAROTID-BODY CHEMORECEPTORS | PRESERVED EJECTION FRACTION | BAROREFLEX ACTIVATION THERAPY | ANGIOTENSIN-CONVERTING ENZYME | AMINOPEPTIDASE-A INHIBITORS | RENAL SYMPATHETIC DENERVATION | SOLUBLE EPOXIDE HYDROLASE | ALDOSTERONE-SYNTHASE INHIBITION | RECEPTOR-NEPRILYSIN INHIBITOR | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | AMBULATORY BLOOD-PRESSURE | Kidney Tubules - physiopathology | Antihypertensive Agents - pharmacology | Drugs, Investigational - pharmacology | Sympathetic Nervous System - drug effects | Humans | Drugs, Investigational - therapeutic use | Hypertension - drug therapy | Ion Channels - drug effects | Sympathetic Nervous System - physiopathology | Molecular Targeted Therapy | Receptors, Cell Surface - antagonists & inhibitors | High-Intensity Focused Ultrasound Ablation | Decompression, Surgical | Pre-Eclampsia - prevention & control | Multicenter Studies as Topic | Sympathectomy - methods | Drug Design | Mineralocorticoid Receptor Antagonists - pharmacology | Female | Models, Animal | Hypertension - enzymology | Hypertension - therapy | Stents | Kidney Tubules - drug effects | Arteriovenous Shunt, Surgical | Carotid Body - surgery | Comorbidity | Enzyme Inhibitors - pharmacology | Pressoreceptors - physiology | Therapies, Investigational | Renin-Angiotensin System - physiology | Clinical Trials as Topic | Antihypertensive Agents - therapeutic use | Electric Stimulation Therapy | Enzyme Inhibitors - therapeutic use | Hypertension - pathology | Mineralocorticoid Receptor Antagonists - therapeutic use | Randomized Controlled Trials as Topic | Pregnancy | Animals | Pre-Eclampsia - drug therapy | Kidney - innervation | Renin-Angiotensin System - drug effects | Baroreflex - physiology | Oxidative Stress - drug effects | Renal Artery - surgery
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 2009, Volume 75, Issue 5, pp. 1528 - 1536
... has indicated that radiation-induced injuries might be treatable, although no therapies have yet been approved by the Food and Drug Administration (FDA) (2) . Our interest... 
Radiology | Hematology, Oncology and Palliative Medicine | Radiation injury | mitigation | angiotensin-converting enzyme inhibitors | lung function | ACE | INDUCED PNEUMONOPATHY | BRADYKININ B-1 RECEPTOR | ENDOTHELIAL DYSFUNCTION | RAT | INDUCED LUNG INJURY | NEPHROPATHY | CONVERTING-ENZYME-INHIBITORS | ACE-INHIBITORS | IRRADIATION | ONCOLOGY | II TYPE-1 | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiation Pneumonitis - pathology | Angiotensin Receptor Antagonists | Vasodilation - radiation effects | Radiation Pneumonitis - mortality | Respiratory Mechanics - drug effects | Captopril - therapeutic use | Vasoconstriction - physiology | Vasoconstriction - radiation effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Radiation Injuries, Experimental - drug therapy | Female | Lung - radiation effects | Pulmonary Artery - radiation effects | Vasodilation - physiology | Respiratory Mechanics - physiology | Radiation Injuries, Experimental - mortality | Drug Evaluation, Preclinical - methods | Lung - pathology | Rats | Renin-Angiotensin System - physiology | Respiratory Mechanics - radiation effects | Lung - physiopathology | Pulmonary Artery - drug effects | Radiation Dosage | Radiation Injuries, Experimental - pathology | Radiation Pneumonitis - physiopathology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Vasoconstriction - drug effects | Pulmonary Artery - physiology | Captopril - administration & dosage | Animals | Losartan - therapeutic use | Renin-Angiotensin System - drug effects | Losartan - administration & dosage | Vasodilation - drug effects | Radiation Injuries, Experimental - physiopathology | Radiation Pneumonitis - drug therapy | Pneumonia | Bacterial pneumonia | Radiation | Index Medicus | HYDROLASES | RENIN | RADIATION EFFECTS | RATS | CARDIOVASCULAR AGENTS | ANGIOTENSIN | GLOBULINS | BIOLOGICAL EFFECTS | ENZYMES | DRUGS | VERTEBRATES | PNEUMONITIS | BIOLOGICAL RADIATION EFFECTS | MAMMALS | ANIMALS | INJURIES | RODENTS | NONSPECIFIC PEPTIDASES | ENZYME INHIBITORS | ORGANIC COMPOUNDS | RADIATION INJURIES | CHEST | RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS | DISEASES | VASOCONSTRICTORS | MITIGATION | PROTEINS | BODY | PEPTIDE HYDROLASES | angiotensin converting enzyme (ACE) inhibitors
Journal Article
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 2019, Volume 18, Issue 1, pp. 46 - 12
BackgroundSGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight... 
Bioimpedance sprectroscopy | Overhydration | Fluid status | Diabetes mellitus | Renin-angiotensin-aldosterone system | Body composition monitor | SGLT2 inhibitor | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR OUTCOMES | COMBINATION THERAPY | HEART-FAILURE | GLUCOSE COTRANSPORTER-2 INHIBITORS | ADIPOSE DISTRIBUTION | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | FAT | WEIGHT | KIDNEY | EMPAGLIFLOZIN | Prospective Studies | Humans | Middle Aged | Male | Water-Electrolyte Balance - drug effects | Weight Loss - drug effects | Case-Control Studies | Body Water - metabolism | Benzhydryl Compounds - adverse effects | Time Factors | Body Composition - drug effects | Female | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Body Mass Index | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Adiposity - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Treatment Outcome | Electric Impedance | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Renin-Angiotensin System - drug effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Longitudinal Studies | Adipose tissues | Substance abuse treatment | Adipose tissue | Body weight | Systematic review | Aldosterone | Body composition | Renin | Body composition (biology) | Spectrum analysis | Diuretics | Diabetes mellitus (non-insulin dependent) | Heart failure | Urine | Hypertension | Spectroscopy | Stroke | Mortality | Hydrochlorothiazide | Patients | Studies | Inhibitors | Body mass | Weight reduction | Angiotensin | Diabetes | Kidney diseases | Gastrointestinal surgery
Journal Article
Circulation research, ISSN 0009-7330, 02/2007, Volume 100, Issue 3, pp. 342 - 353
A large body of evidence has accrued indicating that voltage-gated Ca channel subtypes, including L-, T-, N-, and P/Q-type, are present within renal vascular... 
Renal microcirculation | Mibefradil | channels | Afferent arteriole | channel blockers | Efferent arteriole | Renal disease | Voltage-dependent Ca | Efonidipine | Ca | Ca2+ channel blockers | N-TYPE | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFERENT ARTERIOLES | efonidipine | SPONTANEOUSLY HYPERTENSIVE-RATS | RHO-KINASE INHIBITOR | renal microcirculation | ANGIOTENSIN-II | T-TYPE | renal disease | mibefradil | DEPENDENT CALCIUM-CHANNELS | CARDIAC L-TYPE | RENAL MICROVASCULAR CONSTRICTION | efferent arteriole | voltage-dependent Ca2+ channels | PERIPHERAL VASCULAR DISEASE | afferent arteriole | HEMATOLOGY | IN-VIVO VISUALIZATION | Arterioles - physiology | Kidney - physiology | Protein Subunits | Antihypertensive Agents - pharmacology | Kidney - blood supply | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Antihypertensive Agents - classification | Calcium Channels - physiology | Calcium Channels, T-Type - chemistry | Neurotransmitter Agents - secretion | Calcium Channels - drug effects | Calcium Channels, N-Type - drug effects | Cardiovascular Diseases - physiopathology | Kidney - drug effects | Calcium Channels - classification | Rats | Calcium Channels, L-Type - physiology | Antihypertensive Agents - therapeutic use | Arterioles - drug effects | Disease Progression | Antihypertensive Agents - adverse effects | Mice, Knockout | Calcium Signaling - drug effects | Diabetes Mellitus - physiopathology | Models, Biological | Calcium Channels - chemistry | Calcium Channels, T-Type - drug effects | Mice | Vasodilation - drug effects | Hydronephrosis - physiopathology | Calcium Channel Blockers - adverse effects | Calcium Signaling - physiology | Cardiovascular Diseases - drug therapy | Renal Circulation - physiology | Microcirculation - drug effects | Microcirculation - physiology | Renal Circulation - drug effects | Blood Pressure - drug effects | Calcium Channels, L-Type - chemistry | Kidney Diseases - metabolism | Calcium Channels, T-Type - physiology | Renin - secretion | Aldosterone - physiology | Kidney Diseases - drug therapy | Renin-Angiotensin System - physiology | Calcium Channel Blockers - pharmacology | Hypertension - physiopathology | Animals | Calcium Channels, L-Type - drug effects | Calcium Channels, N-Type - physiology | Calcium Channels, N-Type - chemistry
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2019, Volume 20, Issue 3, p. 629
The renin-angiotensin system (RAS) plays an important role in regulating body fluids and blood pressure... 
Type 2 diabetes | Renin-angiotensin system (RAS) | Natriuresis | Diuretic effect | Sodium glucose cotransporter 2 (SGLT2) inhibitor | natriuresis | SELECTIVE SGLT2 INHIBITOR | DAPAGLIFLOZIN | diuretic effect | CIRCADIAN-RHYTHM | BIOCHEMISTRY & MOLECULAR BIOLOGY | URINARY ANGIOTENSINOGEN | renin-angiotensin system (RAS) | CHEMISTRY, MULTIDISCIPLINARY | BLOOD-PRESSURE | sodium glucose cotransporter 2 (SGLT2) inhibitor | type 2 diabetes | CANAGLIFLOZIN | POTENTIAL MECHANISMS | JAPANESE PATIENTS | TYPE-2 DIABETES-MELLITUS | EMPAGLIFLOZIN | Gene Expression - drug effects | Diabetes Mellitus, Type 2 - genetics | Humans | Hypertension - drug therapy | Diabetes Mellitus, Type 2 - metabolism | Hyperglycemia - drug therapy | Hyperglycemia - genetics | Hypoglycemic Agents - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Blood Pressure - drug effects | Hypertension - genetics | Hyperglycemia - physiopathology | Sodium-Glucose Transporter 2 - genetics | Glycosuria - physiopathology | Diuretics - administration & dosage | Glycosuria - drug therapy | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Glycosuria - genetics | Natriuresis - drug effects | Sodium-Glucose Transporter 2 - metabolism | Polyuria - metabolism | Hypertension - physiopathology | Polyuria - chemically induced | Glycosuria - metabolism | Hypertension - metabolism | Hyperglycemia - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Glucose - metabolism | Renin-Angiotensin System - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diuretics - adverse effects | Polyuria - physiopathology | Heart failure | Urine | Phosphorylation | Na+/H+-exchanging ATPase | Aquaporins | Diabetes mellitus | Bicarbonates | Tubules | Reabsorption | FDA approval | Glucose | Studies | Urea | Bicarbonate | Hyperglycemia | Inhibitors | Renin | Sodium | Angiotensin | Diuretics | Blood pressure | Diabetes | Kidney diseases | Aquaporin 2
Journal Article